Portfolio company
ADXS
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops bioengineered immunotherapies and precision small molecule drugs for patients with rare tumors and aggressive cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ALXO
This biopharmaceutical company develops immune system therapies to treat cancer patients with solid tumors and hematologic malignancies.
Clinical stage immunotherapy company
This company develops next-generation antibody-drug conjugates to treat patients with solid tumor malignancies.
Adcytherix
This biopharmaceutical company develops novel antibody-drug conjugates to treat various forms of cancer for patients with high unmet clinical needs.
Adcendo ApS
The company develops antibody-drug conjugates to treat patients with advanced solid tumors and cancers that have high unmet medical needs.
Nuvectis Pharma
This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.
Avenzo
The company develops oncology therapies, including small molecule inhibitors and antibody-drug conjugates, for patients with advanced solid tumours and metastatic breast cancer.
Inhibrx
Inhibrx Biosciences develops biologic therapeutic candidates for patients with various cancers and rare diseases using its proprietary single-domain antibody platform.
ALX Oncology
This clinical-stage biopharmaceutical company develops novel therapies to treat cancer patients by expanding the possibilities of immuno-oncology and antibody-drug conjugates.